Novo Nordisk built modern obesity pharmacology. Liraglutide came first in 2009, with Saxenda following in 2014. Semaglutide split into three products — Ozempic for type-2 diabetes, Wegovy for obesity, and Rybelsus as the oral form. The 2025 and 2026 cadence has been about defending that position against Lilly's tirzepatide while moving the next generation forward.
The May 6 Q1 2026 print landed strong: net sales DKK 96.82B (+24% YoY), operating profit DKK 59.62B (+54%). Wegovy pill drove the upside with DKK 2.26B (~$354M) in Q1 — almost 2× analyst consensus — on roughly 1.3 million Q1 prescriptions and 2 million-plus cumulative since the January 5 launch. CEO Mike Doustdar told CNBC on May 6 that Wegovy holds 65% of all new US GLP-1 prescriptions, calling the moment a 'turnaround situation.' NovoCare priced the 1.5 mg starter at $149/month and moved the 4 mg dose from $149 to $199 effective April 15. On May 1, Novo officially retired the Rybelsus US brand and re-launched the same molecule as Ozempic Pill at 1.5/4/9 mg with improved-absorption reformulation across 70,000+ pharmacies. Wegovy HD 7.2 mg launched April 7 with a STEP UP 21% mean weight loss anchor. Full-year guidance tightened to a 4–12% sales-and-operating-profit decline (from the prior 5–13%) — Jefferies pushed back that the lower-end guidance was not lifted enough to be a positive surprise.
The pipeline gets harder from here. CagriSema (cagrilintide + semaglutide) failed to match Zepbound in February's head-to-head readout (23% vs 25.5%), and the Q1 documents disclosed Novo has discontinued the single-chamber co-formulation device — the dual-chamber injectable system continues with the original FDA filing already submitted and a higher-dose Phase 3 trial slated for H2 2026. Petrelintide and amycretin-prodrug sit further back. The Indian semaglutide patent expired in March 2026 and licensed generics from Biocon and Dr. Reddy's followed within weeks.
International milestones continued through Q2 2026. Japan's MHLW granted Novo Nordisk a partial change approval on June 19, 2026 making Wegovy the first approved MASH treatment in Japan (without cirrhosis, moderate-to-advanced fibrosis), co-promoted with Sumitomo Pharma under the October 2025 co-promotion agreement and based on ESSENCE Phase 3 Part 1 data. France joined the UK and Switzerland with public-insurance reimbursement effective June 15, 2026 at 65% Sécurité Sociale coverage, and the UAE became the first ex-US Wegovy pill launch on June 3.
September 7, 2026 was a split-decision day. STEP Young reported that 40.4% of children aged 6 to under 12 with obesity achieved a BMI below the obesity threshold at week 68 on semaglutide plus lifestyle modification, versus 0% on placebo, with safety consistent with adult and adolescent trials and no signal on growth or pubertal development — potentially opening a supplemental filing path to extend Wegovy below its current 12-and-older label. On the same day the company confirmed it had terminated the HERMES and ATHENA Phase 3 heart failure trials of ziltivekimab (anti-IL-6 monoclonal antibody) early after a data monitoring committee ruled the studies unlikely to succeed, following the June 2026 ZEUS miss. A post-acute heart-failure study of ziltivekimab remains ongoing, but the non-GLP-1 diversification story has narrowed further.
Analyst sentiment split further into the week of September 8-11. HSBC raised its Novo Nordisk target to DKK 320 from DKK 300 (Hold, September 9) after early-week positive newsflow, and Barclays cut its target from DKK 310 to DKK 300 (Equal Weight, September 8) after the STEP Young + ziltivekimab split announcement. Morgan Stanley's Thibault Boutherin then downgraded Novo to Underweight from Equal-weight on Friday September 11, cutting the price target to DKK 250 (implying more than 10% downside) on concerns that current valuation does not reflect the subdued mid-term growth outlook or the semaglutide patent-cliff impact on Novo's terminal value. Morgan Stanley flagged that semaglutide is expected to account for approximately 75% of 2026 sales, with loss of exclusivity beginning in 2031, and cited weaker U.S. Wegovy pill script momentum after a stronger first half. Novo shares closed the week down 2.8% in Copenhagen at DKK 278.2 and 3.1% in Frankfurt at EUR 36.89. The company continued executing the DKK 15 billion share repurchase programme (DKK 9.02 billion completed through September 4).
On Monday September 14, 2026 the company said it would use 'Novo' as its day-to-day name, while Novo Nordisk A/S remains its legal name. The rebrand introduced the platform 'Lasting Health Starts Now,' an updated version of the Apis bull logo, and a culture framework called The Novo Way, and the company said it would give more detail on its strategy at a Capital Markets Day in London on September 21. On Wednesday September 16, Novo and Anthropic announced a collaboration under which Novo will test Anthropic's Claude Science in research and development workflows; financial terms were not disclosed. On Thursday September 17, Novo signed a multi-target discovery and license agreement with Orbis Medicines, a Copenhagen and Lausanne company that designs oral macrocycle drugs, worth up to $1.4 billion in upfront and milestone payments plus tiered royalties, along with a strategic investment of undisclosed size. Orbis's chief executive said its macrocycles have reached up to 18% oral bioavailability in preclinical studies.
Novo set out its 2030 ambitions at the Capital Markets Day in London on Monday September 21, 2026: launch more than five multi-blockbusters, run at least five Phase 3 programs in obesity and diabetes and at least five in other therapy areas, serve more than 60 million patients, build capacity to serve 10 times more people with obesity on oral GLP-1, keep a broadly stable operating margin, and grow revenue from 2026 to 2030 in line with industry peers. It also targets more than DKK 150 billion (about $23 billion) in pipeline sales in 2035 and said the ambitions are not financial guidance. Management said CagriSema would launch early next year, followed by standalone cagrilintide and high-dose CagriSema in 2028, with zenagamtide planned in oral and injectable forms. Shares fell as much as 9% during the day, BNN Bloomberg reported, as management faced questions on pricing and dealmaking.
In Novo Nordisk's trial of 167 children aged 6 to under 12 with obesity, all of whom also received diet and activity counseling, BMI fell 17.4% on Wegovy and rose 2.2% on placebo at 68 weeks for children who stayed on treatment, CNBC reported. Counting those who stopped, the gap was 16.2 percentage points. Novo said it saw no safety concerns for growth or puberty. No obesity drug is approved for children under 12, and Novo's Andrea Traina called long-term effects of earlier treatment "still an evidence gap."
Novo Nordisk's analysis of 5,872 adults on the Ro telehealth platform who had never used a weight-loss drug and stayed on the daily Wegovy pill for three months found average weight loss of 6.2%, or 6.3 kg from a starting weight of 103.0 kg, Reuters reported via CTV News. About three in five lost at least 5% and roughly one in six lost at least 10%. Novo's scientific chief Martin Holst Lange said the result broadly matched the 5.5% seen at 12 weeks in the pill's late-stage trial.
In a post hoc analysis that Novo Nordisk announced on November 15 and presented at ObesityWeek, 67.8% of people on CagriSema 2.4 mg/2.4 mg lost at least 5% of their weight by week 8. These early responders lost an average of 25.4% by week 68, compared with 17.8% for those who responded later, based on observed on-treatment data the company calls hypothesis-generating. In a separate post hoc analysis, 73.1% on CagriSema versus 49.1% on placebo reported a meaningful improvement in physical function. An FDA decision is expected in the fourth quarter of 2026.
In 309 adults with obesity or overweight and no diabetes, CagriSema 1.7 mg/1.7 mg and 1.0 mg/1.0 mg led to 20.7% and 21.0% average weight loss at 68 weeks if everyone stayed on treatment, versus 2.0% on placebo, Novo Nordisk said at ObesityWeek. Counting everyone regardless of adherence, losses were 19.4% and 18.6% versus 4.6%. The trial was not powered to compare the two doses. Results appeared in The Lancet Diabetes & Endocrinology, and an FDA decision on the 2.4 mg/2.4 mg dose is expected this quarter.
In SIGNAL, 26,213 adults starting Wegovy injections through the Ro telehealth platform reported lower scores on a seven-item food noise questionnaire within the first month, a mean drop of 0.42 points from a baseline of 2.72. In OCTANE, 7,669 adults starting the Wegovy pill saw average scores fall from 2.8 to 2.1 over three months. Novo, which presented both retrospective analyses at ObesityWeek, noted that they rely on self-reported data and cannot show cause and effect.
Medsafe has received an application for Wegovy oral tablets under one of its reliance pathways, which draw on decisions by trusted overseas regulators to halve target review times, and aims to finish the initial assessment in about 75 working days, 1News reported on November 7. No other weight-loss drug is under consideration, and the Royal New Zealand College of General Practitioners' medical director, Dr. Prabani Wood, said no decision has been made on funding and access.
Under an expanded agreement announced November 5, Abbott will promote and distribute Plosbrio, semaglutide made by Novo Nordisk under a second brand name for Ozempic, for adults with type 2 diabetes in Singapore and other Asia Pacific countries. Abbott already sells Extensior, another second brand of Ozempic, in India, and the companies have linked Abbott's FreeStyle Libre glucose monitors with Novo's connected insulin pens since 2019.
Novo Nordisk reported third-quarter Wegovy pill sales of 5.4 billion Danish kroner (about $811 million), above the roughly 4.5 billion analysts expected, CNBC reported on November 4. Total sales rose 4% at constant exchange rates to 79.2 billion kroner, and Novo now expects 2026 adjusted sales and operating profit growth of -2% to +2%, up from a range of -6% to flat; the company said the pill is now sold in eight countries. CFO Karsten Munk Knudsen will leave at the end of 2026 after 27 years, to be replaced by Galderma's Luigi La Corte, and CEO Mike Doustdar said "turnaround and recovery is not done based on one data point."
The Therapeutic Goods Administration approved Novo Nordisk's oral semaglutide tablet on Tuesday, November 3, in 1.5, 4, 9, and 25 mg strengths for adults with obesity and for lowering cardiovascular risk, ABC News reported. The TGA still has to review packaging and production before the pill can be released, no price has been set, and under current rules the Pharmaceutical Benefits Scheme subsidizes these drugs only for type 2 diabetes. Eli Lilly's orforglipron is still awaiting a TGA decision.
The FDA cleared insulin icodec-abae 700 U/mL, approved for adults in March 2026, to improve blood sugar control in children aged 10 and older with type 2 diabetes. Healio reported the decision rested on the adult ONWARDS trials plus a single-dose study of how the drug moves through the body in children aged 10 to 17. The approval does not cover type 1 diabetes.
U.S. District Judge Zahid Quraishi in Trenton, New Jersey refused on October 26, 2026 to issue a preliminary injunction against Eli Lilly's ads for Zepbound and Mounjaro, which Novo Nordisk sued over in July for comparing higher doses of Lilly's drugs with lower doses of Wegovy and Ozempic, Reuters reported. After a two-day hearing in late August, the judge found Novo had not shown the ads hurt its sales, goodwill, or clinical reputation, noting its prescriptions stayed stable from April to July and that money damages could cover any harm. He did not decide whether the ads are false or misleading; Novo said the litigation continues, and Lilly, which denies wrongdoing, said it was pleased.
Novo Nordisk presented post hoc analyses of its Phase 3 REDEFINE 1 trial at The Menopause Society's annual meeting on October 20, 2026, Reuters reported: among 2,309 women with obesity or overweight, CagriSema 2.4 mg/2.4 mg was linked to 25% average weight loss at 68 weeks versus 3% on placebo, compared with 22.7% across the full trial of more than 3,400 adults. In 1,902 women grouped by menopause stage, average loss was 26.7% before menopause, 24.8% during perimenopause, and 23.1% after. Novo called the analyses hypothesis-generating; an FDA decision on CagriSema for weight management is expected in the fourth quarter of 2026.
At the Aging Research and Drug Discovery (ARDD) meeting at Harvard on October 1-3, 2026, Novo Nordisk researchers reported that in protein data from 10,052 participants in five semaglutide trials, the drug lowered an estimate of heart biological age by about 2 to 4 years at the first follow-up measurement, according to the meeting's poster abstracts. Longevity.Technology reported on October 4 that Novo also modeled SELECT trial results in a UK cohort of 19,117 people to project 1.9 life-years gained, and that a Lilly epigenetic substudy with 71 paired SURMOUNT-5 participants found all 15 epigenetic clocks showed less aging than the 1.38 years that had passed, two of them statistically significant. Lilly called its work preliminary and hypothesis-generating, with no placebo or control group, and biological-age clocks are not established clinical outcomes.
Novo Nordisk reported on Thursday, October 1, 2026, at EASD in Milan, a post hoc, exploratory analysis pooling 1,919 adults from its STEP UP and STEP UP T2D trials who took Wegovy 7.2 mg, Wegovy 2.4 mg, or placebo. In a 55-person subgroup whose liver fat was measured by MRI, average liver fat fell from 8.8% at baseline to 3.1% at week 72, and 23 of the 26 participants who started above the 5% threshold for fatty liver ended below it. Liver fat was not a prespecified endpoint of either trial, and Novo pooled the two Wegovy doses for the MRI result.
Novo Nordisk said on Friday, October 2, 2026 that the FDA's review of its biologics license application for denecimig, a bispecific antibody that mimics activated clotting factor VIII in hemophilia A, is still ongoing with no new action date because of remediation work at a manufacturing facility. Novo filed in September 2025 and had expected a decision in the third quarter of 2026; the FDA has not identified deficiencies in the clinical efficacy or safety data, and Novo now aims to launch in the U.S. in the first half of 2027. The company said the delay does not change its 2026 financial outlook.
Full results of Novo's REMODEL trial, first presented at the 2026 World Congress of Nephrology, were published in Nature Medicine on Thursday, October 1, 2026. The trial randomized 106 adults with type 2 diabetes and chronic kidney disease to semaglutide 1 mg weekly or placebo for 52 weeks to learn how the drug protects the kidneys. Its coprimary MRI measures of kidney oxygenation, perfusion, and inflammation did not change significantly versus placebo, but semaglutide lowered the renal artery resistive index and kept stable an MRI marker the authors link to scarring, and paired biopsies showed marked effects on the cells lining the kidney's filtering blood vessels, with fewer immune cells nearby. Urine albumin fell 40% in an exploratory analysis; Novo Nordisk funded the trial.
Novo presented at EASD on Wednesday, September 30, 2026 OCTANE, a retrospective analysis of de-identified data from the telehealth company Ro covering 194 adults who switched from injectable semaglutide or tirzepatide to the once-daily Wegovy pill between January 5 and February 7, 2026. From a mean baseline weight of 100.5 kg and BMI of 34.5, participants lost an average of 4.1% of body weight (4.0 kg) over three months, 40.7% lost at least 5%, and the share with a BMI of 30 or higher fell from 87.1% to 65.5%. Novo listed limitations including self-reported and incomplete data and selection bias from counting only people who stayed on treatment; the release did not give the injectable doses people switched from.
Novo and Jiangsu Hengrui Pharmaceuticals announced on Tuesday, September 29, 2026 an exclusive license giving Novo global rights to HRS-1596, a GLP-1/GIP dual receptor agonist being developed for once-weekly oral dosing, outside mainland China, Hong Kong, Macao, and Taiwan, where Hengrui keeps the rights. Novo will pay $300 million upfront, and the deal is worth up to $2.6 billion including development, regulatory, and commercial milestones, plus royalties on sales. HRS-1596 is described as Phase 1-ready for weight management and type 2 diabetes; the deal requires Hart-Scott-Rodino clearance and is expected to close in the fourth quarter of 2026. Novo R&D chief Martin Holst Lange said the company wants to explore whether the drug can 'raise the bar for convenience.'